Percutaneous closure of the left atrial appendage using the amplatzer cardiac plug in patients with atrial fibrillation: Evaluation of safety and feasibility

Kardiologia Polska

Volumn 71, Issue 1, 2013, Pages 8-16

  Streb, Witold ^a   Szymaa, Magdalena ^a   Kukulski, Tomasz ^a   Nowak, Jolanta ^a   Lekston, Andrzej ^a   Sokal, Adam ^a   Knapik, Piotr ^a   Czapla, Jerzy ^a   Zbieralska, Ewa ^a   Kalarus, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Amplatzer Cardiac Plug; Atrial fibrillation; Closure of the left atrial appendage; Stroke

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMORBIDITY; ECHOCARDIOGRAPHY; FEASIBILITY STUDY; FEMALE; FLUOROSCOPY; HEART ATRIUM FIBRILLATION; HEART TAMPONADE; HUMAN; IMPLANTATION; MALE; PATIENT SAFETY; PERICARDIOCENTESIS; RISK FACTOR; SEPTAL OCCLUDER; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION;

EID: 84872893858     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Go AS, Hylek EM, Phillips KA at al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001; 285: 2370-2375.
2. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation, 1998; 98: 946-952.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991; 22: 983-988.
4. Huey-Juan Lin, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke, 1996; 27: 1760-1764.
5. Camm AJ, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010; 31: 2369-2429.
6. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm, 2009; 15: 244-252.
7. Okumara K, Komatsu T, Yamashita T et al. Time In the therapeutic range Turing warfarin therapy In Japanese patients with non-valvular atrial fibrillation - a multicenter study of its status and influential factors. Circ J, 2011; 75: 2087-2094.
8. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation incommunity-based practise. Thromb Haemost, 2008; 6: 1647-1654.
9. Granger CB, Alexander JH, McMurray JJ et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011; 365: 981-992.
10. Connolly SJ, zekowitz MD, Yusuf S et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009; 361: 1139-1151.
11. Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart, 1999; 82:547-554.
12. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg, 1996; 61: 755-759.
13. Bayard YL, Omran H, Neuzil P et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention, 2010; 6: 220-226.
14. Kukua K, Kopotowski M, Konka M et al. Left atrial appendage occlusion using the PLAATO system in high-risk patients with atrial fibrillation: long-term follow-up. Post Kardiol Interw, 2009; 5: 51-57.
15. Ostermayer SH, Reisman M, Kramer PH et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol, 2005; 46: 9-14.
16. Holmes DR, Reddy VY, Turi ZG et al. PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet, 2009; 37: 534-542.
17. Viles-Gonzalez JF, Kar S, Douglas P et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol, 2012; 59: 923-929.
18. Park JW, Bethencourt A, Sievert H et al. Left atrial appendage closure with Amplatzer Cardiac Plug in atrial Fibrillation: initial European experience. Catheterization Cardiovascular Interventions, 2011; 77: 700-706.
19. Lam YY, Yip GWK, Yu C-M et al. Left atrial appendage closure with Amplatzer Cardiac Plug for stroke prevention In atrial fibrillation: initial Asia-Pacific experiance. Catheterization Cardiovascular Interventions, 2011: doi: 10.1002/ccd.23136.
20. Reddy VY, Holmes D, Doshi SK et al. Safety of percutaneous left atrial appendage closure. Results from the Watchamn left atrial appendage system for embolic protection in patients with AF (PROTECT AF) Clinical Trial and the Continued Access Registry. Circulation, 2011; 123: 417-424.